AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Neutra Corp.

$0 +$0.00 (+50.00%)
OTC · 14 Sep 2026 20:00 UTC
Previous Close
$0
Day Range
$0 - $0
Year Range
$0$0
Market Cap
437.69K
AVG Volume
1.27M
Trailing/Forward PE
1.5/-
PEG ratio
0.01
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (USD)
0100K200K300K400K24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR Revenue (USD) by quarter
PeriodRevenue (USD)
27 Q1352.81K
26 Q4200K
26 Q3351.84K
26 Q2271.58K
26 Q1200.08K
25 Q4951
25 Q38.57K
25 Q226.16K
25 Q132.38K
24 Q428.06K
Net Income (USD)
-1M01M2M24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR Net Income (USD) by quarter
PeriodNet Income (USD)
27 Q184.5K
26 Q41.26M
26 Q3-341.32K
26 Q217.35K
26 Q1-947.48K
25 Q4-35.36K
25 Q3-24.73K
25 Q2-32.58K
25 Q1-16.35K
24 Q4-34.64K
Operating Income (USD)
-1M-500K0500K1M24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR Operating Income (USD) by quarter
PeriodOperating Income (USD)
27 Q1117.11K
26 Q4836.5K
26 Q3129.08K
26 Q222.01K
26 Q1-900.11K
25 Q4-34.45K
25 Q3-23.78K
25 Q2-31.7K
25 Q1-15.48K
24 Q4-33.78K
EBITDA (USD)
-1M-500K0500K1M24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR EBITDA (USD) by quarter
PeriodEBITDA (USD)
27 Q1118.38K
26 Q4838.3K
26 Q3130.35K
26 Q223.28K
26 Q1-899.37K
25 Q4-34.45K
25 Q3-23.83K
25 Q2-31.7K
25 Q1-14.36K
24 Q4-27.36K
Cash Flows (USD)
-20K020K40K60K80K24 Q124 Q224 Q324 Q425 Q126 Q126 Q226 Q326 Q427 Q1
NTRR Cash Flows (USD) by quarter
PeriodCash Flows (USD)
27 Q165.28K
26 Q42.56K
26 Q311.58K
26 Q2-5.9K
26 Q125.91K
25 Q1-1.3K
24 Q4940
24 Q3-442
24 Q2-2K
24 Q1-8.83K
EPS (USD)
-0-0-0-0024 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR EPS (USD) by quarter
PeriodEPS (USD)
27 Q10
26 Q40
26 Q30
26 Q20
26 Q1-0
25 Q40
25 Q30
25 Q20
25 Q10
24 Q40
Expenses (USD)
-250K0250K500K750K1MSG&ACapex24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR Expenses (USD) by quarter
PeriodExpenses (USD)
24 Q30
24 Q20
24 Q10
27 Q1166K
26 Q4175.75K
26 Q3112.72K
26 Q2140.75K
26 Q1946K
25 Q434.62K
25 Q331.78K
25 Q256.93K
25 Q145.32K
24 Q436.62K
Cash & Debt (USD)
0100K200K300KCashLong Term DebtShort Term Debt24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR Cash & Debt (USD) by quarter
PeriodCash & Debt (USD)
27 Q149.91K
26 Q459.54K
26 Q335.58K
26 Q250.87K
26 Q156.77K
25 Q4385
25 Q37.33K
25 Q2554
25 Q1333
24 Q41.97K
Debt ratios
-1-0.500.5124 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR Debt ratios by quarter
PeriodDebt ratios
27 Q10.06
26 Q40.6
26 Q3-0.1
26 Q2-0.18
26 Q1-0.17
25 Q4-0.52
25 Q3-0.48
25 Q2-0.46
25 Q1-0.37
24 Q4-0.29
Margins
0%50%100%150%24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR Margins by quarter
PeriodMargins
27 Q180.24%
26 Q4104.95%
26 Q368.73%
26 Q259.75%
26 Q121.38%
25 Q417.67%
25 Q393.39%
25 Q296.43%
25 Q195.61%
24 Q433.01%
Return on Capital
-600%-400%-200%0%200%24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR Return on Capital by quarter
PeriodReturn on Capital
27 Q1-53.68%
26 Q4-582.91%
26 Q361.17%
26 Q2-1.39%
26 Q174.77%
25 Q43.28%
25 Q32.37%
25 Q23.2%
25 Q11.66%
24 Q43.57%
Shares Outstanding
01B2B3B4B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR Shares Outstanding by quarter
PeriodShares Outstanding
27 Q12.92B
26 Q43.04B
26 Q32.08B
26 Q22.92B
26 Q12.92B
25 Q42.92B
25 Q32.92B
25 Q22.92B
25 Q12.92B
24 Q42.92B
Book Value Per Share (USD)
-0-0-0-024 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR Book Value Per Share (USD) by quarter
PeriodBook Value Per Share (USD)
27 Q1-0
26 Q4-0
26 Q3-0
26 Q2-0
26 Q1-0
25 Q4-0
25 Q3-0
25 Q2-0
25 Q1-0
24 Q4-0
Total Assets (USD)
0100K200K300K24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
NTRR Total Assets (USD) by quarter
PeriodTotal Assets (USD)
27 Q1248.75K
26 Q4172.24K
26 Q3213.78K
26 Q2134.03K
26 Q195.04K
25 Q4385
25 Q37.33K
25 Q2554
25 Q1431
24 Q42.85K
Employee Count
0510152020212022
NTRR Employee Count by quarter
PeriodEmployee Count
202215
202115
PE Ratio
0.20.40.60.8med 0.37Oct 16Dec 16Jan 17Feb 17Apr 17Jul 26Sep 26
NTRR PE Ratio by quarter
PeriodPE Ratio
Sep 260.43
Sep 260.28
Aug 260.43
Aug 260.28
Aug 260.28
Aug 260.57
Jul 260.28
May 170.2
May 170.21
Apr 170.25
Apr 170.28
Apr 170.3
Apr 170.26
Mar 170.29
Mar 170.35
Mar 170.33
Mar 170.33
Mar 170.37
Feb 170.55
Feb 170.52
Feb 170.38
Feb 170.57
Jan 170.6
Jan 170.59
Jan 170.42
Jan 170.46
Dec 160.37
Dec 160.31
Dec 160.27
Dec 160.3
Dec 160.34
Nov 160.43
Nov 160.49
Nov 160.53
Nov 160.53
Oct 160.53
Oct 160.69
Free Cash Flow Yield
-60%-40%-20%0%20%40%med -1.12%Jun 23Oct 23Jan 24May 24Aug 24May 26Sep 26
NTRR Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 2616.8%
Sep 2625.2%
Aug 2616.8%
Aug 2625.2%
Aug 2625.2%
Aug 2612.6%
Jul 2625.2%
Jul 2611.22%
Jul 2611.22%
Jul 2611.22%
Jul 265.61%
Jun 265.61%
Jun 2611.22%
Jun 2611.22%
Jun 2611.22%
May 2611.22%
May 267.48%
May 267.48%
May 267.48%
May 2611.22%
Oct 24-0.96%
Oct 24-0.96%
Oct 24-0.96%
Oct 24-0.48%
Sep 24-0.48%
Sep 24-0.96%
Sep 24-0.96%
Sep 24-0.48%
Aug 24-0.48%
Aug 24-0.48%
Aug 24-0.48%
Aug 24-0.48%
Aug 24-1.77%
Jul 24-1.34%
Jul 24-1.34%
Jul 24-1.34%
Jul 24-1.34%
Jun 24-1.67%
Jun 24-1.34%
Jun 24-1.12%
Jun 24-1.67%
May 24-1.12%
May 24-1.12%
May 24-1.12%
May 24-1.12%
May 24-0.84%
Apr 24-1.67%
Apr 24-0.84%
Apr 24-0.84%
Apr 24-1.12%
Mar 24-1.12%
Mar 24-1.12%
Mar 24-0.96%
Mar 24-1.12%
Mar 24-0.96%
Feb 24-1.12%
Feb 24-0.84%
Feb 24-1.12%
Feb 24-1.29%
Jan 24-1.12%
Jan 24-1.34%
Jan 24-1.34%
Jan 24-1.12%
Dec 23-1.12%
Dec 23-1.12%
Dec 23-0.84%
Dec 23-3.72%
Dec 23-3.72%
Nov 23-3.72%
Nov 23-3.19%
Nov 23-3.19%
Nov 23-2.79%
Oct 23-3.72%
Oct 23-3.72%
Oct 23-3.72%
Oct 23-2.79%
Sep 23-2.23%
Sep 23-2.79%
Sep 23-2.79%
Sep 23-4.77%
Sep 23-5.96%
Aug 23-5.96%
Aug 23-5.96%
Aug 23-5.96%
Aug 23-5.96%
Jul 23-3.97%
Jul 23-4.77%
Jul 23-5.96%
Jul 23-6.81%
Jun 23-4.77%
Jun 23-3.97%
Jun 23-11.17%
Jun 23-9.31%
Jun 23-30.1%
May 23-22.58%
May 23-22.58%
May 23-45.15%
May 23-22.58%
Apr 23-30.1%
Apr 23-22.58%
Price to Sales
051015med 2.48Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
NTRR Price to Sales by quarter
PeriodPrice to Sales
Sep 260.37
Sep 260.25
Aug 260.37
Aug 260.25
Aug 260.25
Aug 260.5
Jul 260.25
Jul 260.3
Jul 260.3
Jul 260.3
Jul 260.59
Jun 260.59
Jun 260.3
Jun 260.3
Jun 260.3
May 260.3
May 260.45
May 260.45
May 260.45
May 260.3
Apr 260.25
Apr 260.25
Apr 260.5
Apr 260.38
Mar 260.25
Mar 260.38
Mar 260.5
Mar 260.5
Feb 260.25
Feb 260.5
Feb 260.25
Feb 260.5
Jan 260.5
Jan 260.91
Jan 261.21
Jan 260.61
Jan 260.61
Dec 251.21
Dec 251.21
Dec 251.21
Dec 250.61
Nov 251.21
Nov 250.61
Nov 250.61
Nov 251.82
Oct 251.21
Oct 253.71
Oct 252.48
Oct 252.48
Oct 251.24
Sep 253.71
Sep 253.71
Sep 252.48
Sep 252.48
Aug 252.48
Aug 252.48
Aug 251.24
Aug 252.48
Aug 251.24
Jul 258.57
Jul 258.57
Jul 2512.86
Jul 2512.86
Jun 254.29
Jun 254.29
Jun 256.43
Jun 258.57
May 254.29
May 254.29
May 258.57
May 258.57
May 2512.86
Apr 256.13
Apr 256.13
Apr 259.2
Apr 256.13
Mar 259.2
Mar 256.13
Mar 256.13
Mar 259.2
Feb 256.13
Feb 253.07
Feb 256.13
Feb 256.13
Jan 256.13
Jan 256.64
Jan 259.96
Jan 259.96
Jan 258.3
Dec 246.64
Dec 249.96
Dec 246.64
Dec 246.64
Nov 243.32
Nov 243.32
Nov 243.32
Nov 243.32
Nov 243.32
Oct 244.42
Oct 244.42
EV/EBITDA
02468med 0.69Oct 16Dec 16Feb 17Apr 17May 26Jul 26Sep 26
NTRR EV/EBITDA by quarter
PeriodEV/EBITDA
Sep 260.45
Sep 260.32
Aug 260.45
Aug 260.32
Aug 260.32
Aug 260.58
Jul 260.32
Jul 263.89
Jul 263.89
Jul 263.89
Jul 267.18
Jun 267.18
Jun 263.89
Jun 263.89
Jun 263.89
May 263.89
May 265.53
May 265.53
May 265.53
May 263.89
May 170.37
May 170.39
Apr 170.45
Apr 170.49
Apr 170.52
Apr 170.45
Mar 170.5
Mar 170.59
Mar 170.56
Mar 170.56
Mar 170.61
Feb 170.89
Feb 170.84
Feb 170.63
Feb 170.91
Jan 170.97
Jan 170.95
Jan 170.69
Jan 170.75
Dec 160.61
Dec 160.52
Dec 160.46
Dec 160.5
Dec 160.57
Nov 160.7
Nov 160.79
Nov 160.85
Nov 160.86
Oct 160.86
Oct 161.09
Price/Operating Cashflow
05101520med 8.91May 26May 26Jun 26Jul 26Jul 26Aug 26Sep 26
NTRR Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Sep 266.22
Sep 264.14
Aug 266.22
Aug 264.14
Aug 264.14
Aug 268.29
Jul 264.14
Jul 268.91
Jul 268.91
Jul 268.91
Jul 2617.82
Jun 2617.82
Jun 268.91
Jun 268.91
Jun 268.91
May 268.91
May 2613.36
May 2613.36
May 2613.36
May 268.91
Neutra Corp.
NTRR
Stockpicker

Video analysis: NTRR

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: NTRR

Neutra Corp's Neutra Life Sciences Expands 2026 Industry Conference Schedule to Deepen Sponsor and CRO Relationships Across Its Site Network

globenewswire.com · 14 Sep 2026

Neutra Corp's Neutra Life Sciences Expands 2026 Industry Conference Schedule to Deepen Sponsor and CRO Relationships Across Its Site Network

HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced that its wholly owned clinical research Site Management Organization (SMO) subsidiary, Neutra Life Sciences (“NLS”), has expanded its 2026 industry conference schedule with the addition of three new events — Partnership with Sites, DPharm: Disruptive Innovations to Advance Clinical Trials, and Fall Clinical – Dermatology — as part of its ongoing strategy to deepen sponsor and CRO relationships and expand trial opportunities across its growing site network.

Neutra Corp Targets Expanded Sponsor and CRO Relationships in Q3 & Q4 2026, Reaffirming Full Commitment to Life Sciences Growth

globenewswire.com · 13 Jul 2026

Neutra Corp Targets Expanded Sponsor and CRO Relationships in Q3 & Q4 2026, Reaffirming Full Commitment to Life Sciences Growth

HOUSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced its forward-looking strategy for the third and fourth quarters of 2026, centered on deepening relationships with clinical trial sponsors and Contract Research Organizations (CROs). Neutra Corp has committed its full resources to the growth and expansion of Neutra Life Sciences, its wholly owned clinical research Site Management Organization (SMO) subsidiary, as the Company's primary strategic priority for the remainder of 2026 and beyond.

Neutra Corp's Subsidiary Neutra Life Sciences Executes New Women's Health Joint Venture and Expands Trial Portfolio

globenewswire.com · 29 Jun 2026

Neutra Corp's Subsidiary Neutra Life Sciences Executes New Women's Health Joint Venture and Expands Trial Portfolio

HOUSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced a series of operational milestones at its wholly owned subsidiary, Neutra Life Sciences, a clinical research Site Management Organization (SMO). Following its 2025 launch and early-stage growth, Neutra Life Sciences has proven its operational excellence with multiple clinical trial.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.